ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: RFA: Cancer Research Network Across Health Care Systems

September 12, 1997

House Appropriations For NCI Identical (So Far) To White House Request; Slight Increase for NIH

June 24, 1988

ASBMT Installs New Officers

March 14, 2003

Funding Opportunity: Stand Up To Cancer Canada to Fund Two Dream Teams

October 17, 2014

First Panel Meeting On Centers Generates Possible Recommendations For Core Grant Guideline Changes

April 6, 1984

Cornel Student Withdraws In Wake Of Discrepancies Found In Study

September 18, 1981